en
Scientific article
Open access
English

Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy

Published inCore evidence, vol. 11, p. 37-47
Publication date2016
Abstract

Gaucher disease is the first lysosomal disease to benefit from enzyme replacement therapy, thus serving as model for numerous other lysosomal diseases. Alglucerase was the first glucocerebrosidase purified from placental extracts, and this was then replaced by imiglucerase - a Chinese hamster ovary cell-derived glucocerebrosidase.

Citation (ISO format)
DE ROUX SERRATRICE, Christine et al. Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy. In: Core evidence, 2016, vol. 11, p. 37–47. doi: 10.2147/CE.S93717
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal1555-1741
407views
172downloads

Technical informations

Creation11/09/2016 12:29:00 PM
First validation11/09/2016 12:29:00 PM
Update time03/15/2023 1:04:25 AM
Status update03/15/2023 1:04:24 AM
Last indexation05/02/2024 5:59:45 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack